ArticleNature2024
Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
22.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 98 citations in OpenAlex.
- Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release.Cancer research · 2026Article
- Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation.Signal transduction and targeted therapy · 2026Review
- DNA binding contributes to dominant-negative effects of a catalytically inactive RecQ4-family helicase.Nucleic acids research · 2026Article
- High-Content CRISPR Screening: Methods and Applications.MedComm · 2026Review
- Paediatric therapeutic development workshop on osteosarcoma.British journal of cancer · 2026Review
- Phenols: From Replacing to Embracing.ChemMedChem · 2026Review
- Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors.Molecular cancer therapeutics · 2026Article
- Palladium-catalyzed Suzuki-Miyaura and Buchwald-Hartwig cross-coupling reactions towards the synthesis of pharmacologically potent pyrimidine-based molecules.Molecular diversity · 2026Review
- A multidimensional pan-cancer analysis of CD47 and its role in promoting malignant phenotype in pancreatic adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Cryo-EM structures of human FANCJ reveal the mechanism of G-quadruplex unwinding and disease-associated mutations.Nature communications · 2026Article
- Unlocking the ferroptotic window: Lipidomic rewiring and metabolic addiction in EMT-driven breast cancer resistance.Cell death discovery · 2026Review
- Context-dependent synthetic lethality - an emerging precision therapeutic approach.Nature reviews. Cancer · 2026Review
- Differential DNA damage response to WRN inhibition identifies a targetable vulnerability inScience advances · 2026Article
- Loss of CHTF18-RFC2/5 leads to replicative gaps and sensitivity to PARP inhibitors.NAR cancer · 2026Article
- Using cancer profiles to identify synthetic lethal therapeutic targets and predictive biomarkers in cancer gene dependency data.Bioinformatics (Oxford, England) · 2026Article
- 3D chromatin architecture in cancer: mechanisms of dysregulation and emerging therapeutic strategies.Experimental & molecular medicine · 2026Review
- Insights into the therapeutic strategies for aging and aging-associated diseases.Signal transduction and targeted therapy · 2026Review
- Reprogramming T cell-myeloid crosstalk overcomes immune resistance in colorectal cancer.Cell reports. Medicine · 2026Article
- VeGA-RX and VeGA-SCX: Controllable SMARTS-Guided Generative Transformers for Precision-DrivenJournal of chemical information and modeling · 2026Article
- dMMR killer: A conditional suicide gene that preferentially kills DNA mismatch repair-deficient cells.Molecular therapy. Nucleic acids · 2026Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors at 2 institutions in 3 countries.
Stephane Ferretti *Novartis BioMedical Research, Basel, Switzerland.
Jacques Hamon *Novartis BioMedical Research, Basel, Switzerland.
Ruben de Kanter *Novartis BioMedical Research, Basel, Switzerland.ORCID 0000-0001-7503-9776
Clemens Scheufler *Novartis BioMedical Research, Basel, Switzerland.ORCID 0000-0002-3693-3529
Rita Andraos-ReyNovartis BioMedical Research, Basel, Switzerland.
Stephanie BarbeNovartis BioMedical Research, Basel, Switzerland.
Elisabeth BechterNovartis BioMedical Research, Basel, Switzerland.
Jutta BlankNovartis BioMedical Research, Basel, Switzerland.
Vincent BordasNovartis BioMedical Research, Basel, Switzerland.
Ernesta DammassaNovartis BioMedical Research, Basel, Switzerland.
Andrea DeckerNovartis BioMedical Research, Basel, Switzerland.
Noemi Di NanniNovartis BioMedical Research, Basel, Switzerland.
Marion DourdoigneNovartis BioMedical Research, Basel, Switzerland.
Elena GavioliNovartis BioMedical Research, Basel, Switzerland.
Marc HattenbergerNovartis BioMedical Research, Basel, Switzerland.
Alisa HeuserNovartis BioMedical Research, Basel, Switzerland.
Christelle HemmerlinNovartis BioMedical Research, Basel, Switzerland.
Jürgen HinrichsNovartis BioMedical Research, Basel, Switzerland.
Grainne KerrNovartis BioMedical Research, Basel, Switzerland.ORCID 0009-0004-4231-518X
Laurent LabordeNovartis BioMedical Research, Basel, Switzerland.
Isabel JacoNovartis BioMedical Research, Basel, Switzerland.
Eloísa Jiménez NúñezNovartis BioMedical Research, Basel, Switzerland.
Hans-Joerg MartusNovartis BioMedical Research, Basel, Switzerland.
Cornelia QuadtNovartis BioMedical Research, Basel, Switzerland.
Markus ReschkeNovartis BioMedical Research, Basel, Switzerland.
Vincent RomanetNovartis BioMedical Research, Basel, Switzerland.
Fanny SchaefferNovartis BioMedical Research, Basel, Switzerland.
Joseph SchoepferNovartis BioMedical Research, Basel, Switzerland.ORCID 0000-0001-7935-1767
Maxime SchrappNovartis BioMedical Research, Basel, Switzerland.
Ross StrangNovartis BioMedical Research, Basel, Switzerland.
Hans VosholNovartis BioMedical Research, Basel, Switzerland.ORCID 0000-0002-2594-8127
Markus WartmannNovartis BioMedical Research, Basel, Switzerland.ORCID 0009-0007-9822-3112
Sarah WellyNovartis BioMedical Research, Basel, Switzerland.
Frédéric ZécriNovartis BioMedical Research, Cambridge, MA, USA.
Francesco HofmannNovartis BioMedical Research, Basel, Switzerland.
Henrik MöbitzNovartis BioMedical Research, Basel, Switzerland. henrik.moebitz@novartis.com.ORCID 0000-0002-8398-6121
Marta Cortés-CrosNovartis BioMedical Research, Basel, Switzerland. marta.cortes-cros@novartis.com.ORCID 0009-0009-2588-5654
Novartis (Switzerland) · CHNovartis (United States) · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Werner syndrome RecQ helicase WRN was identified as a synthetic lethal target in cancer cells with microsatellite instability (MSI) by several genetic screens
Indexed as
Antineoplastic AgentsDrug DiscoveryEnzyme InhibitorsMicrosatellite InstabilityNeoplasmsSynthetic Lethal MutationsWerner Syndrome HelicaseAdministration, OralAllosteric RegulationAnimalsCell Line, TumorClinical Trials as TopicColorectal NeoplasmsDNA DamageFemaleHumansAntineoplastic AgentsEnzyme InhibitorsTumor Suppressor Protein p53Werner Syndrome HelicaseWRN protein, human
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.